ONCR
Closed
Oncorus inc
0.126
-0.004 (-3.08%)
Last Update: 29 Dec 2023 22:55:00
Yesterday: 0.13
Day's Range: 0. - 0.
Send
sign up or login to leave a comment!
When Written:
0.303
Oncorus Inc is a clinical-stage biotechnology company that is focused on developing next-generation immunotherapy treatments for cancer. The company is headquartered in Cambridge, Massachusetts, and was founded in 2015. Oncorus is developing a platform technology that uses oncolytic viruses to target and destroy cancer cells while also activating the immune system to recognize and attack cancer cells. The company's lead product candidate, ONCR-177, is a next-generation oncolytic virus therapy that is being developed for the treatment of various solid tumors. Oncorus has also developed a proprietary delivery system that enables the targeted delivery of oncolytic viruses to tumors. The company has raised over $190 million in funding from investors, including Deerfield Management, MPM Capital, and Perceptive Advisors.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!
When Written:
0.303
Oncorus Inc is a clinical-stage biotechnology company that specializes in developing oncolytic virus therapies for the treatment of cancer. The company's lead product candidate is ONCR-177, which is designed to selectively target and destroy cancer cells while leaving healthy cells unharmed. ONCR-177 is currently being evaluated in a Phase 1 clinical trial for the treatment of solid tumors. Oncorus also has a pipeline of other oncolytic virus candidates in preclinical development. The company was founded in 2016 and is headquartered in Cambridge, Massachusetts.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!








